Boston Scientific Co. (NYSE:BSX) Shares Purchased by Sei Investments Co.

Sei Investments Co. increased its position in shares of Boston Scientific Co. (NYSE:BSX) by 3.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,710,266 shares of the medical equipment provider’s stock after purchasing an additional 137,397 shares during the period. Sei Investments Co. owned 0.32% of Boston Scientific worth $362,739,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. Precision Wealth Strategies LLC acquired a new stake in Boston Scientific during the fourth quarter worth about $956,000. Aveo Capital Partners LLC increased its position in Boston Scientific by 1.3% during the fourth quarter. Aveo Capital Partners LLC now owns 12,841 shares of the medical equipment provider’s stock worth $742,000 after purchasing an additional 171 shares during the last quarter. Jump Financial LLC acquired a new stake in Boston Scientific during the fourth quarter worth about $361,000. TrinityPoint Wealth LLC increased its position in Boston Scientific by 5.9% during the fourth quarter. TrinityPoint Wealth LLC now owns 12,546 shares of the medical equipment provider’s stock worth $725,000 after purchasing an additional 697 shares during the last quarter. Finally, Gladstone Institutional Advisory LLC acquired a new stake in Boston Scientific during the fourth quarter worth about $239,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Citigroup increased their target price on shares of Boston Scientific from $90.00 to $92.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, September 13th. The Goldman Sachs Group assumed coverage on shares of Boston Scientific in a research note on Thursday, May 30th. They set a “buy” rating and a $90.00 target price for the company. Truist Financial increased their target price on shares of Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Finally, Evercore ISI increased their target price on shares of Boston Scientific from $78.00 to $81.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 2nd. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $85.38.

Insiders Place Their Bets

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $74.12, for a total transaction of $517,579.96. Following the sale, the executive vice president now owns 40,188 shares of the company’s stock, valued at $2,978,734.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 20,949 shares of company stock valued at $1,627,877. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Up 0.3 %

Shares of Boston Scientific stock opened at $83.92 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $84.89. The company has a 50 day moving average of $78.72 and a 200 day moving average of $74.63. The company has a market capitalization of $123.12 billion, a P/E ratio of 70.52, a P/E/G ratio of 2.75 and a beta of 0.79.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The company had revenue of $4.12 billion for the quarter, compared to analysts’ expectations of $4.02 billion. During the same quarter last year, the company earned $0.53 earnings per share. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, research analysts forecast that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.